424 related articles for article (PubMed ID: 37375228)
1. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.
Kong Y; Jiang C; Wei G; Sun K; Wang R; Qiu T
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375228
[TBL] [Abstract][Full Text] [Related]
2. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal aberrations and fusion genes in myeloid malignancies.
Gianfelici V; Lahortiga I; Cools J
Expert Rev Hematol; 2012 Aug; 5(4):381-93. PubMed ID: 22992233
[TBL] [Abstract][Full Text] [Related]
4. Targeting chromatin complexes in fusion protein-driven malignancies.
Brien GL; Stegmaier K; Armstrong SA
Nat Rev Cancer; 2019 May; 19(5):255-269. PubMed ID: 30962549
[TBL] [Abstract][Full Text] [Related]
5. ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors.
Biswas A; Rajesh Y; Mitra P; Mandal M
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188389. PubMed ID: 32659251
[TBL] [Abstract][Full Text] [Related]
6. Targeting tropomyosin-receptor kinase fused gene in cancer.
Chen Y; Tseng SH
Anticancer Res; 2014 Apr; 34(4):1595-600. PubMed ID: 24692687
[TBL] [Abstract][Full Text] [Related]
7. TRKing down an old oncogene in a new era of targeted therapy.
Vaishnavi A; Le AT; Doebele RC
Cancer Discov; 2015 Jan; 5(1):25-34. PubMed ID: 25527197
[TBL] [Abstract][Full Text] [Related]
8. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
9. Targeting cancer with kinase inhibitors.
Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
[TBL] [Abstract][Full Text] [Related]
10. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Barry ER; Corry GN; Rasmussen TP
Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
[TBL] [Abstract][Full Text] [Related]
11. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
12. Commonality but diversity in cancer gene fusions.
Rabbitts TH
Cell; 2009 May; 137(3):391-5. PubMed ID: 19410533
[TBL] [Abstract][Full Text] [Related]
13. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
14. Targeting oncogenic ALK: a promising strategy for cancer treatment.
Grande E; Bolós MV; Arriola E
Mol Cancer Ther; 2011 Apr; 10(4):569-79. PubMed ID: 21474455
[TBL] [Abstract][Full Text] [Related]
15. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
[TBL] [Abstract][Full Text] [Related]
16. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
Vaishnavi A; Schubert L; Rix U; Marek LA; Le AT; Keysar SB; Glogowska MJ; Smith MA; Kako S; Sumi NJ; Davies KD; Ware KE; Varella-Garcia M; Haura EB; Jimeno A; Heasley LE; Aisner DL; Doebele RC
Cancer Res; 2017 Jul; 77(13):3551-3563. PubMed ID: 28428274
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
18. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
19. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
20. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]